RESUMEN
Bovine Respiratory Disease (BRD) poses a significant threat to cattle welfare worldwide, affecting their respiratory system and causing substantial economic losses. BRD is multifactorial in nature. This research aimed to investigate the serological profile of calves for the five main bovine respiratory pathogens. Serum samples were collected from dairy calves aged 7-12 months that had never been vaccinated against tested pathogens and had recently shown signs of BRD. A total of 4095 calves from 650 dairy herds located in south-western Poland were examined. The Commercial Indirect Respiratory ELISA Kit Multiplexed-Double well-BIO K 284/5 (Bio-X Diagnostics, Rochefort, Belgium) was used to determine the presence of antibodies against BVDV, BoAHV1, BRSV, BPIV3, and M. bovis. The presence of antibodies against at least one of the tested pathogens was found in 306 (47.08%) herds. The overall prevalence of antibodies was as follows: BoAHV1 21.54%, BVDV 32.0%, BRSV 34.15%, BPIV3 34.31%, and M. bovis 31.38%. The strongest correlation was between BRSV antibodies positive sera and BPIV3 antibodies positive sera. Among the five pathogens tested, antibodies to BVDV, BRSV, BPIV3, and M. bovis were most commonly detected simultaneously. The results of this study indicate the need for preventive measures against these pathogens in the studied region.
RESUMEN
Bovine respiratory disease (BRD) is a very important disease that contributes to economic losses in dairy and beef cattle breeding worldwide. The molecular testing of material from 296 calves showing BRD symptoms from 74 dairy herds located in south-western Poland was performed in 2019-2021. Molecular tests were performed using a commercial kit "VetMAXTM Ruminant Respiratory Screening Kit" (Thermo Fisher Scientific) for the simultaneous detection of genetic material of seven pathogens responsible for BRD. At least one pathogen was detected in 95.95% of herds. The overall prevalence was: Pasteurella multocida 87.84%, Mannheimia haemolytica 44.59%, bovine coronavirus (BcoV) 32.43%, Mycoplasma bovis 29.73%, Histophilus somni 28.38%, bovine parainfluenza virus type 3 (BPIV-3) 13.51%, and bovine respiratory syncytial virus (BRSV) 10.81%. Twenty-nine configurations of pathogen occurrences were found. Bacterial infections were the most frequently recorded as 56.7% of all results. Coinfections mainly consisted of two pathogens. Not a single purely viral coinfection was detected. The most frequent result was a single P. multocida infection accounting for 18.31% of all results. The statistically significant correlation (p = 0.001) with the highest strength of effect (Ï 0.38) was between M. bovis and H. somni.
RESUMEN
(1) Background: The objective of the study was to evaluate the long-term antibody response of dairy cows to a single dose of a commercial modified-live virus (MLV) vaccine against bovine viral diarrhea (Mucosiffa® CEVA Sante Animale, Liburne, France). (2) Methods: The study was carried out in a dairy cattle herd counting 290 animals negative for bovine viral diarrhoea virus (BVDV). The vaccination was implemented following the manufacturer's instructions. Twelve dairy cows were randomly selected before the study, and blood samples were collected right before the vaccination and then 12 times at 1-month intervals. The serum samples were screened using a virus neutralization test (VNT) and ELISA. (3) Results: Both tests showed that antibody titers increased significantly in all animals within the first month post-vaccination, and continued to increase significantly until the second (VNT) and third (ELISA) month post-vaccination. Antibody titers remained high and stable until the end of the study. Moreover, cows did not show any adverse reactions or clinical symptoms of the disease. (4) Conclusion: The results of this study indicated that the administration of one dose MLV vaccine was able to stimulate long-lasting (12-months) and strong antibody response in all vaccinated cows.
RESUMEN
Background: Maternal colonization of Streptococcus agalactiae in pregnancy constitute an important clinical problem, that may result in serious consequences, especially for the newborn. Streptococcus agalactiae is a gram-positive beta-hemolytic streptococci belonging to the serological group B (GBS). According to recent data the GBS is found in 10-30% of healthy women, and the carriage of pathogen is usually asymptomatic. In order to minimize the risk of vertical transmission of the infection to the newborn during the labor, the Polish Society of Gynecology (PTG) has introduced the guidelines of GBS colonization screening for all pregnant women. Objectives: In this paper, the level of implementation of the screening tests in accordance to the recommendations of the PTG was evaluated. We also assessed the level of knowledge and awareness of pregnant women in detection of GBS colonization during the pregnancy and the prevention of infection in newborn. Material and method: The survey was conducted among the 172 women hospitalized in hospital maternity wards in the first days of postpartum. Results: Despite the introduction of the Polish Society of Gynecology guidelines, there are still cases of improper screening methods and medical interventions in the event of positive test results. Biological material was collected in 86% of patients (swabs from the genital tract, anus or urine culture). A positive result was found in 22% of patients. In 54% of patients swabs were taken at the recommended period of 35-37 weeks. The recommended collection of the material both from vagina and anus was taken only in 39% of patients. The majority of participated women described their knowledge of the risk associated with group B Streptococcal colonization as good, however only half of them found acquired information sufficient. Despite the implementation of guidelines Polish Gynaecological Society the incorrect conduct of the prevention against GBS is still performed in some cases. Conclusion: It is appropriate to perform consciousnessraising campaigns on screening of GBS among patients and doctors.